Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 6.31B P/E 54.83 EPS this Y 22.40% Ern Qtrly Grth 1.90%
Income 79.4M Forward P/E 26.38 EPS next Y 11.60% 50D Avg Chg -20.00%
Sales 2.02B PEG 2.88 EPS past 5Y 0.16% 200D Avg Chg -24.00%
Dividend N/A Price/Book 4.74 EPS next 5Y 11.90% 52W High Chg -40.00%
Recommedations 2.00 Quick Ratio 0.98 Shares Outstanding 53.47M 52W Low Chg 13.00%
Insider Own 8.17% ROA 3.00% Shares Float 44.21M Beta 0.98
Inst Own 93.38% ROE 5.93% Shares Shorted/Prior 2.92M/6.75M Price 119.52
Gross Margin 49.28% Profit Margin 3.94% Avg. Volume 744,135 Target Price 155.00
Oper. Margin 5.70% Earnings Date Nov 5 Volume 873,473 Change -1.58%
About Masimo Corporation

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

Masimo Corporation News
11/14/24 Masimo to Present in the Jefferies London Healthcare Conference
11/13/24 Masimo to Present in Stifel 2024 Healthcare Conference
11/11/24 Beat the Market Like Zacks: Sprouts Farmers Market, Kroger, Masimo in Focus
11/07/24 Is There An Opportunity With Masimo Corporation's (NASDAQ:MASI) 44% Undervaluation?
11/07/24 Masimo Third Quarter 2024 Earnings: EPS Misses Expectations
11/06/24 Masimo's Q3 Earnings Rise Y/Y, Healthcare Demand Drives Growth
11/06/24 MASI Stock Gains Following Q3 Earnings Beat, Gross Margin Expands
11/06/24 Q3 2024 Masimo Corp Earnings Call
11/06/24 Masimo, amid leadership transition, targets cost reductions
11/06/24 Masimo Corp (MASI) Q3 2024 Earnings Call Highlights: Strong Healthcare Growth Amid ...
11/05/24 Masimo (MASI) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
11/05/24 Masimo (MASI) Q3 Earnings and Revenues Top Estimates
11/05/24 Masimo: Q3 Earnings Snapshot
11/05/24 Masimo Reports Third Quarter 2024 Financial Results
11/04/24 Exploring Analyst Estimates for Masimo (MASI) Q3 Earnings, Beyond Revenue and EPS
11/01/24 Masimo (MASI): A Promising Medical Stock with Growth Potential
10/30/24 Analysts Estimate Tandem Diabetes Care, Inc. (TNDM) to Report a Decline in Earnings: What to Look Out for
10/29/24 Masimo Terminates Founder Kiani as CEO
10/29/24 Masimo (MASI) Reports Next Week: Wall Street Expects Earnings Growth
10/29/24 Vanderbilt University Medical Center Integrates Masimo Radius VSM™ in Proactive Care Protocol to Combat Emergency Room Congestion
MASI Chatroom

User Image Thestocktraderhubzee Posted - 2 days ago

$MASI Stifel Reiterates Buy on Masimo, Raises Price Target to $190

User Image FlynancialAnalyst Posted - 2 weeks ago

$MASI $8.70B mc $XLV name still needs a lot of work imo, but keep an eye on it. Significant accumulation this year, now trading at 1yr highs LONG-time (1990s) founder led, 8.15% insider owned. I'll be watching for a nearly certain sharp rise in Pct of all funds long shares following this week's fresh data Short float % trending lower YTD TrendEdge.app/asset/MASI

User Image Luii_133 Posted - 2 weeks ago

$MASI 37% since this

User Image 1986iamwallstreet Posted - 2 weeks ago

$MASI dying business here

User Image DonCorleone77 Posted - 2 weeks ago

$MASI Masimo raises FY24 EPS view to $3.95-$4.10 from $3.80-$4.00 Consensus $3.88. Cuts FY24 revenue view to $2.075B-$2.105B form $2.085B-$2.135B, consensus $2.1B.

User Image DonCorleone77 Posted - 2 weeks ago

$MASI Masimo sees Q4 adjusted EPS $1.35-$1.50, consensus $1.41 Sees Q4 revenue $581M-$611M, consensus $607.35M.

User Image DonCorleone77 Posted - 2 weeks ago

$MASI Masimo reports Q3 adjusted EPS 98c, consensus 84c Reports Q3 revenue $504.6M, consensus $502.67M. Michelle Brennan, Interim Chief Executive Officer of Masimo, said, "We are pleased to report strong third quarter performance, driven by our core healthcare segment. We appreciate the commitment and energy of our employees, which has resulted in a seamless transition since our Annual Meeting with no disruption to our business or departures of critical talent. Our focus is on positioning Masimo to achieve its significant long-term growth potential by capitalizing on the many opportunities we see ahead of us, including through our ongoing review of the product portfolio and R&D projects. We are allocating resources to fewer projects, concentrating on sizable market opportunities that address clear unmet needs, and reducing spending in areas that are not contributing to our long-term growth objectives. We are also progressing on our strategic review of the consumer business and are focused on delivering the best outcome for our shareholders. We are confident in our position as we approach the end of 2024, as demonstrated by our increased full-year non-GAAP operating margin and EPS guidance. With the support of our talented team and our newly expanded Board, we will continue to execute on our strategy while enhancing shareholder value as we look to next year and beyond."

User Image 1986iamwallstreet Posted - 2 weeks ago

$MASI lower revenue. Flush city …..

User Image ChessGM Posted - 3 weeks ago

$MASI Heads up alert! Only three days until Upcoming Earnings on Tuesday, 11/5/2024 Bearish (2.5) In the case of Masimo Corporation (NASDAQ: MASI), recent developments suggest a challenging landscape for the company. The termination of CEO Joe Kiani, following a contentious proxy battle with activist investors, raises concerns about the company's leadership stability. While Masimo has reported positive expectations regarding earnings growth and has received a price target increase from BTIG, the overall sentiment appears dampened by the leadership change and its potential impact on operational continuity. Financial metrics indicate that Masimo's P/E ratio stands at approximately 30, reflecting a premium valuation relative to the industry average of around 25. This premium is supported by a projected EPS growth rate of 12% for the upcoming year, suggesting optimism in its earnings potential. However, revenue forecasts have become less certain, especially after a jury ruled in favor of Apple in a patent infringement case against Masimo, which may affect future sales of its smartwatch products. Comparatively, the broader MedTech sector is experiencing robust growth, but Masimo faces headwinds that could hinder its competitiveness. Upcoming earnings reports are expected to reveal third-quarter financial results on November 5, 2024. Analysts are largely optimistic, with consensus estimates predicting a slight increase in revenue, driven by strong demand for Masimo's innovative medical devices. Historically, the company has shown a solid track record of beating earnings estimates, which may provide some reassurance to investors amid current uncertainties. The market will keenly watch the conference call for insights into how the leadership transition is being managed and its implications for future growth. Given the mixed signals surrounding Masimo's outlook, the potential impact of the earnings report will be crucial in determining the stock's direction in the near term. - Funds were net buyers of $MASI during the previous reporting quarter. - Top 5 funds with large holdings in $MASI: * RTW Investments LP $184MM. CGMRank: 61% * Westfield Capital Management Company LP $143MM. CGMRank: 82% * Farallon Capital Management LLC $141MM. CGMRank: 69% * Holocene Advisors LP $131MM. CGMRank: 85% * Point72 Asset Management LP $85MM. CGMRank: 86% - Last 10 days performance: 0% - Last 30 days performance: 6% - Last 90 days performance: 35% Follow ChessGM! Make your move and get timely earnings alerts from ChessGM. Not a financial advice.

User Image contangoz Posted - 10/29/24

CEO BOOTED $MASI

User Image swingingtech Posted - 10/28/24

$NPCE $MASI https://wallstreetwaves.com/strength-seen-in-neuropace-npce-can-its-5-1-jump-turn-into-more-strength/

User Image swingingtech Posted - 1 month ago

$MASI https://wallstreetwaves.com/exploring-intriguing-masi-options-strategies-for-june-2025-puts-and-calls/

User Image WeeklyTrader Posted - 1 month ago

Brace yourself, $MASI is dropping! RSI: 70.47% 50-day MA: $123.65 200-day MA: $126.11

User Image WeeklyTrader Posted - 1 month ago

What’s your vibe on $MASI today? RSI: 67.02% 50-day MA: $122.89 200-day MA: $125.96

User Image WeeklyTrader Posted - 1 month ago

t’s spill the tea on $MASI's rise!

User Image DonCorleone77 Posted - 09/30/24

$AAPL $MASI Apple rethinking approach to headsets, Bloomberg reports Apple (AAPL) is considering options for its headsets, including keeping the Vision Pro more or less the same but focusing on a less expensive version, Bloomberg's Mark Gurman reports. The company could also follow up with a second-generation version of the original, higher-end Vision Pro that has a new chip and Apple Intelligence. Apple could remove the on-board computer and external battery from the Vision Pro and shift many of the internal functions over to the iPhone. Apple is working on a new version of the AirPods Pro that uses external cameras and artificial intelligence to understand the outside world and provide information to the user, Gurman says. Apple could ultimately release some or all of these products, but Gurman says there isn't a consensus on how it will approach the headsets, but says that the resignation of Masimo (MASI) CEO Joe Kiani could open the door for lawyers from Apple and Masimo to work out a deal to bring blood-oxygen sensing back to new Apple Watches.

User Image David4W Posted - 09/26/24

$MASI what a play by Koffey…

User Image JackDarwin Posted - 09/25/24

$MASI Nice Gap Up Formed.

User Image MaverikIT Posted - 09/25/24

@IsabellaDC @net0trader $MASI $DUOL

User Image DonCorleone77 Posted - 09/25/24

$MASI Masimo provides update on consumer business review The company said, "The Board remains committed to the previously announced review of alternatives for both the consumer audio and consumer healthcare businesses. The Board has engaged Centerview Partners and Morgan Stanley as financial advisors and Sullivan & Cromwell as a legal advisor. The Board looks forward to providing updates in the near-term regarding value-creation initiatives, including this strategic review."

User Image DonCorleone77 Posted - 09/25/24

$MASI Masimo backs Q3 adjusted EPS view 81c-86c, consensus 83c Backs Q3 revenue view $495M-$515M, consensus $502.19M. CFO Micah Young and COO Bilal Muhsin, added: "We are excited about the strong momentum of the business and its future prospects for growth. We look forward to providing more details on the upcoming third quarter earnings call next month."

User Image Stock_Titan Posted - 09/25/24

$MASI Masimo Provides Leadership and Business Updates https://www.stocktitan.net/news/MASI/masimo-provides-leadership-and-business-9yh8pwokp4gr.html

User Image Medical12 Posted - 2 months ago

$MASI this is not a good sign for me, but I am wishing Masimo good luck as am still invested.

User Image Atlsutiger Posted - 2 months ago

$MASI CEO was voted off the board yesterday. Politan wins 2 board seats and effectively removes Joe Kiani as CEO.

User Image Stock_Titan Posted - 2 months ago

$MASI Politan Comments on Results of Masimo’s 2024 Annual Meeting https://www.stocktitan.net/news/MASI/politan-comments-on-results-of-masimo-s-2024-annual-z7di28csqao7.html

User Image Stock_Titan Posted - 2 months ago

$MASI Masimo Shares Final Thoughts Ahead of September 19 Annual Meeting Where Everything is at Stake https://www.stocktitan.net/news/MASI/masimo-shares-final-thoughts-ahead-of-september-19-annual-meeting-5k45vxmn1nvi.html

User Image Stock_Titan Posted - 2 months ago

$MASI Politan Comments on Masimo’s Latest Attempt to Block a Fair Shareholder Vote https://www.stocktitan.net/news/MASI/politan-comments-on-masimo-s-latest-attempt-to-block-a-fair-oa86yi5wzg1r.html

User Image DonCorleone77 Posted - 2 months ago

$MASI $QCOM $GOOG $GOOGL Masimo, Qualcomm to develop next-gen smartwatch reference platform for OEMs Masimo (MASI) and Qualcomm Technologies (QCOM), whose Snapdragon branded platforms power extraordinary consumer experiences, announced that Masimo is partnering with Qualcomm Technologies to develop a next-generation smartwatch reference platform for original equipment manufacturers building Wear OS by Google (GOOGL) smartwatches. The reference platform will allow OEMs to more efficiently build and bring high-performing, premium smartwatches to market. The platform will also benefit from Masimo health and wellness tracking tools that consumers can trust to provide accurate, reliable data; it will use exclusively high-performance and ultra-low power system-on-a-chips alongside industry-leading wireless and cellular communications from Qualcomm Technologies to enable a superior connectivity experience.

User Image Stock_Titan Posted - 2 months ago

$MASI Masimo Partners with Qualcomm to Develop Next-Generation Smartwatch Reference Platform for Original Equipment Manufacturers https://www.stocktitan.net/news/MASI/masimo-partners-with-qualcomm-to-develop-next-generation-smartwatch-zdrxh3hhxuh2.html

User Image Stock_Titan Posted - 2 months ago

$MASI Masimo Issues Statement Following Court’s Order Holding Politan and Quentin Koffey in Contempt and Finding Politan Made False Statements to Stockholders https://www.stocktitan.net/news/MASI/masimo-issues-statement-following-court-s-order-holding-politan-and-h32n0fdjewhr.html

Analyst Ratings
Needham Hold Sep 25, 24
Needham Hold Sep 20, 24
Piper Sandler Overweight Aug 7, 24
Needham Hold Aug 7, 24
Needham Hold Jul 9, 24
Piper Sandler Overweight Jun 3, 24
Piper Sandler Neutral May 8, 24
Needham Hold May 8, 24
Stifel Buy Apr 15, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
KIANI JOE E CEO and Chairman of.. CEO and Chairman of the Board May 25 Buy 157.5 6,365 1,002,488 366,055 05/30/23
KIANI JOE E CEO and Chairman of.. CEO and Chairman of the Board Nov 14 Buy 124.3 31,994 3,976,854 39,778 11/15/22
KIANI JOE E CEO and Chairman of.. CEO and Chairman of the Board Nov 11 Buy 129.28 7,784 1,006,316 7,784 11/15/22
Mikkelson Adam Director Director Jan 24 Sell 214.80 600 128,880 1,751 01/26/22
Mikkelson Adam Director Director Jan 10 Sell 250.01 600 150,006 2,951 01/12/22
KIANI JOE E CEO and Chairman of.. CEO and Chairman of the Board Nov 03 Sell 290.17 4,373 1,268,913 612,613 11/05/21
KIANI JOE E CEO and Chairman of.. CEO and Chairman of the Board Oct 26 Sell 290.63 49,785 14,469,015 30,619 10/28/21
REYNOLDS CRAIG B Director Director Jan 13 Sell 279.74 10,000 2,797,400 4,300 01/13/21
REYNOLDS CRAIG B Director Director Jan 13 Option 23.04 10,000 230,400 14,300 01/13/21
KIANI JOE E CEO and Chairman of.. CEO and Chairman of the Board Jan 11 Sell 280.81 63,274 17,767,972 83,807 01/11/21
Sampath Anand EVP, Ops & Clinical.. EVP, Ops & Clinical Research Dec 17 Option 26.39 30,000 791,700 28,782 12/17/20
Sampath Anand EVP, Ops & Clinical.. EVP, Ops & Clinical Research Dec 17 Sell 265.59 30,000 7,967,700 13,782 12/17/20
KIANI JOE E CEO and Chairman of.. CEO and Chairman of the Board Dec 10 Option 28.03 57,336 1,607,128 160,606 12/10/20
KIANI JOE E CEO and Chairman of.. CEO and Chairman of the Board Dec 07 Option 28.03 100,000 2,803,000 170,929 12/07/20
KIANI JOE E CEO and Chairman of.. CEO and Chairman of the Board Dec 07 Sell 262.32 100,000 26,232,000 159,241 12/07/20
Young Micah W EVP & Chief Financia.. EVP & Chief Financial Officer Oct 21 Option 84.97 10,000 849,700 10,000 10/21/20
Young Micah W EVP & Chief Financia.. EVP & Chief Financial Officer Oct 21 Sell 239 10,000 2,390,000 10/21/20